ppar γ agonist (MedChemExpress)
MedChemExpress is a verified supplier 
MedChemExpress manufactures this product 
95
Structured Review
MedChemExpress
ppar γ agonist
Ppar γ Agonist, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 41 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/troglitazone/Troglitazone/pmc13083572-56-41-46
Average 95 stars, based on 41 article reviews
Ppar γ Agonist, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 41 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/troglitazone/Troglitazone/pmc13083572-56-41-46
Average 95 stars, based on 41 article reviews
ppar γ agonist - by Bioz Stars,
2026-10
95/100 stars
Images
1) Product Images from "Promoting APC function of B cells via reprogramming the fatty acid metabolism enhances anticancer immunity in metastatic ovarian cancer"
Article Title: Promoting APC function of B cells via reprogramming the fatty acid metabolism enhances anticancer immunity in metastatic ovarian cancer
Journal: Cancer Immunology, Immunotherapy : CII
doi: 10.1007/s00262-026-04387-y
Figure Legend Snippet: The enhanced APC function of B cells by OA in vitro is achieved through H3K27ac-mediated upregulation of PPAR γ expression. A Protein expression of β -actin and H3K27ac in 3 w OvCa-bearing mouse ascitic CD19 + B cells pretreated with BMS and treated with OA was assessed by WB. β -Actin was used as the internal control to calculate the relative expression level of H3K27ac. B The enrichment percentage of H3K27ac at the PPAR γ , CD80, CD86, and CD83 promoter regions was quantified using ChIP-seq analysis. C Correlation analysis of PPAR γ and APC function-related genes (CD80, CD86, CD83, MHC II) in B cells in OvCa patients in the TCGA database (n = 426). D Analysis of protein interaction among FABP4, PPAR γ , CD80, CD86, and CD83. E The enrichment percentage of PPAR γ at the CD80, CD86, and CD83 promoter regions was quantified using ChIP-seq analysis. F Mean fluorescence intensity of CD80, CD86, and CD83 in 3 w OvCa-bearing mouse ascitic CD19 + B cells pretreated with BMS, GW9662/Trog, and treated with OA was detected by flow cytometry. AS, Ascites; Ag, Antigen; OA, oleic acid; BMS, BMS309403. Data are presented as the mean ± SD of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns, not significant
Techniques Used: In Vitro, Expressing, Control, ChIP-sequencing, Fluorescence, Flow Cytometry
Figure Legend Snippet: The mechanism diagram of combining adoptive immunotherapy with APC-function-enhanced B cells and LDC improves anticancer immunity in metastatic OvCa mice. In vitro, OA enhances the expression of CD80/CD86/CD83 of B cells through the H3K27ac-mediated upregulation of PPAR γ expression. Then, the B cells are adoptively transferred into the abdominal cavity of metastatic OvCa mice. In the abdominal cavity, LDC facilitates the APC function of the transferred B cells by causing apoptosis of cancer cells. The transferred B cells promote the activation, proliferation, and differentiation of T cells, which release higher levels of effector molecules (IL-2, GZMB, and IFN- γ , etc.), and facilitate the formation of lymphoid aggregates, finally improving anticancer immunity. LDC, low-dose chemotherapy
Techniques Used: In Vitro, Expressing, Activation Assay
Related Articles
other:Article Title: PPARG-centric transcriptional re-wiring during differentiation of human trophoblast stem cells into extravillous trophoblasts Article Snippet: The following were used: T0070907 (Selleck Chemicals, S2871; 1 μM), Article Title: Structural Elucidation and Covalent Modulation of the Autorepressed Orphan Nuclear Receptor NR2F6 Article Snippet: 9-cis-retinoic acid was ordered from Sigma Aldrich. Article Title: Fluoropolymer-Mediated Delivery of a Dual TSHR/IGF1R-Targeting CRISPR-Cas9 System for Localized Therapy in Thyroid-Associated Ophthalmopathy. Article Snippet: Thyroid-associated ophthalmopathy (TAO), a vision-threatening and disfiguring autoimmune orbital disorder, remains a therapeutic challenge due to the lack of therapies with orbital specificity, sustained efficacy, and minimal side effects.. Herein, we present G4F7-CRISPR, a fluoropolymer-based CRISPR-Cas9 delivery platform engineered for localized and efficient disruption of thyroid-stimulating hormone receptor (TSHR) and insulin-like growth factor 1 receptor (IGF1R), two key mediators of TAO pathogenesis.. G4F7-CRISPR achieved high insertion/deletion frequencies in primary orbital fibroblasts (Tshr: 37.2%; Igf1r: 42.8%) and mature adipocytes (Tshr: 22.4%; Igf1r: 24.3%), and maintained robust editing efficiency in orbital adipose tissue of TAOmouse models (Tshr: 30.7%; Igf1r: 32.4%). Article Title: Generation and applications of an expandable and mature hiPSC-derived liver organoid Article Snippet: Troglitazone (HY-50935), benzbromarone (HY-B1135), acetaminophen (APAP, HY-66005), trovafloxacin (HY-A0170), cyclosporin A (HY-B0579), rifampicin (HY-B0272), rosiglitazone (HY-17386), levofloxacin (HY-B0330), elafibranor (HY-16737), liraglutide (HY-P0014), metformin (HY-B0627), obeticholic acid (HY-12222), saroglitazar (HY-19937), Nile red (HY-D0718), and Article Title: A novel synthetic bile acid derivative inhibits hepatitis B virus infection at entry step by interfering with the oligomerization of sodium taurocholate co-transporting polypeptide. Article Snippet: Hepatitis B virus (HBV) infection is a major global health burden worldwide despite the availability of an effective vaccine and effective anti-HBV drugs.. The currently approved anti-HBV drugs—i.e., nucleos(t)ide analogues and pegylated interferon α—can effectively suppress HBV replication, but rarely achieve a functional cure.. Accordingly, new anti-HBV agents targeting different aspects of the HBV life cycle are needed. Article Title: Generation and applications of an expandable and mature hiPSC-derived liver organoid Article Snippet: Troglitazone (HY-50935), benzbromarone (HY-B1135), acetaminophen (APAP, HY-66005), trovafloxacin (HY-A0170), cyclosporin A (HY-B0579), rifampicin (HY-B0272), rosiglitazone (HY-17386), levofloxacin (HY-B0330), elafibranor (HY-16737), liraglutide (HY-P0014), metformin (HY-B0627), obeticholic acid (HY-12222), saroglitazar (HY-19937), Nile red (HY-D0718), and |